MSD suspends vaccines supplies to Russia
US pharma giant Merck & Co (NYSE: MRK), known as MSD outside of the USA and Canada, has stopped its supplies of vaccines against chickenpox, rubella, measles and mumps to Russia but will continue sales of its drugs that do not have Russian analogues, reports The Pharma Letter’s local correspondent.
According to Russian Kommersant business paper, MSD sent out notices to its partners in Russia about termination of supplies of varicella vaccines (Varivax), as well as vaccines against measles, rubella, and mumps (M-M-R II) to Russia.
Back in 2019, MSD agreed on the localization of production for vaccines against chicken pox, rotavirus infection (RotaTeq) and human papilloma virus (Gardasil) at the Forta site of the Russian company Nacimbio. Earlier, representatives of Nacimbio said that the work with MSD on the project has been stopped, and the capacities of the Fort site are being used for the production of seasonal vaccines.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze